Literature DB >> 24598963

Use of a stent-graft and vascular occlude to treat primary and re-entry tears in a patient with a Stanford type B aortic dissection.

Huihua Shi, Min Lu, Mier Jiang.   

Abstract

Thoracic endovascular aortic repair for aortic dissections is recognized as an effective treatment. We herein report the case of a 72-year-old male with a Stanford type B aortic dissection. A stent-graft and double-disk vascular occluder was used to repair the primary and re-entry tears, respectively. At 3 month postoperatively, computed tomographic angiography revealed no endoleaks, the stent-graft and vascular occluder to be in optimal positions, the false lumen was almost completely thrombosed, and the visceral arteries were patent. This case illustrates that it is feasible to treat re-entry tears with a vascular occluder after primary proximal stent-graft repairs.

Entities:  

Mesh:

Year:  2013        PMID: 24598963      PMCID: PMC4389426          DOI: 10.5935/1678-9741.20130089

Source DB:  PubMed          Journal:  Rev Bras Cir Cardiovasc


  18 in total

1.  Patient outcomes and thoracic aortic volume and morphologic changes following thoracic endovascular aortic repair in patients with complicated chronic type B aortic dissection.

Authors:  Iden David Andacheh; Carlos Donayre; Fiezel Othman; Irwin Walot; George Kopchok; Rodney White
Journal:  J Vasc Surg       Date:  2012-05-27       Impact factor: 4.268

2.  Mortality within the endovascular treatment in Stanford type B aortic dissections.

Authors:  Alexandre Fioranelli; Alvaro Razuk Filho; Valter Castelli Júnior; Walter Karakhanian; José Maria Pereira de Godoy; Roberto Augusto Caffaro
Journal:  Rev Bras Cir Cardiovasc       Date:  2011 Apr-Jun

3.  Platypnea-orthodeoxia syndrome after failed percutaneous closure of secundum atrial septal defect.

Authors:  M Carmen Gomez-Rubin; Jose Ruiz-Cantador; Luz Polo; Teresa Lopez-Fernandez; Ana Gonzalez; Jose M Oliver; Jose L Lopez-Sendon
Journal:  Congenit Heart Dis       Date:  2012-02-20       Impact factor: 2.007

4.  Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) trial.

Authors:  Christoph A Nienaber; Hervé Rousseau; Holger Eggebrecht; Stephan Kische; Rossella Fattori; Tim C Rehders; Günther Kundt; Dierk Scheinert; Martin Czerny; Tilo Kleinfeldt; Burkhart Zipfel; Louis Labrousse; Hüseyin Ince
Journal:  Circulation       Date:  2009-12-07       Impact factor: 29.690

5.  Late migration of percutaneous bio-absorbable devices--a word of caution.

Authors:  Giulia V Vottero; Lars Niclauss; Carlos Marcucci; Michel Hurni; Ludwig K von Segesser
Journal:  J Card Surg       Date:  2011-12-05       Impact factor: 1.620

6.  Endovascular repair of a type B aortic dissection with a ventricular septal defect occluder.

Authors:  Guangqi Chang; Huishen Wang; Wei Chen; Chen Yao; Zilun Li; Shenming Wang
Journal:  J Vasc Surg       Date:  2010-03-11       Impact factor: 4.268

7.  Midterm results with thoracic endovascular aortic repair for chronic type B aortic dissection with associated aneurysm.

Authors:  Cyrus J Parsa; Judson B Williams; Syamal D Bhattacharya; Walter G Wolfe; Mani A Daneshmand; Richard L McCann; G Chad Hughes
Journal:  J Thorac Cardiovasc Surg       Date:  2011-02       Impact factor: 5.209

8.  Use of a vascular occluder to treat a re-entry tear in a patient with stanford type B aortic dissection: acute and 1-year results.

Authors:  Xiao Tang; Weiguo Fu; Xin Xu; Jue Yang; Yun Shi; Zhipin Yan; Yuqi Wang
Journal:  J Endovasc Ther       Date:  2008-10       Impact factor: 3.487

9.  Transcatheter retrieval of embolized AMPLATZER Septal Occluder.

Authors:  Pravin K Goel; Aditya Kapoor; Aditya Batra; Roopali Khanna
Journal:  Tex Heart Inst J       Date:  2012

10.  Risk factors of incomplete thrombosis in the false lumen after endovascular treatment of extensive acute type B aortic dissection.

Authors:  Yong-Lin Qin; Gang Deng; Tian-Xiao Li; Rui-Wei Jing; Gao-Jun Teng
Journal:  J Vasc Surg       Date:  2012-07-13       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.